ATE509955T1 - Humanisierte kollagen-antikörper und damit verbundene verfahren - Google Patents

Humanisierte kollagen-antikörper und damit verbundene verfahren

Info

Publication number
ATE509955T1
ATE509955T1 AT02795695T AT02795695T ATE509955T1 AT E509955 T1 ATE509955 T1 AT E509955T1 AT 02795695 T AT02795695 T AT 02795695T AT 02795695 T AT02795695 T AT 02795695T AT E509955 T1 ATE509955 T1 AT E509955T1
Authority
AT
Austria
Prior art keywords
related methods
collagen antibodies
cdrs
specific binding
binding activity
Prior art date
Application number
AT02795695T
Other languages
English (en)
Inventor
Jeffry Watkins
William Huse
Ying Tang
Daniel Broek
Peter C Brooks
Original Assignee
Cell Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/995,529 external-priority patent/US7365167B2/en
Application filed by Cell Matrix Inc filed Critical Cell Matrix Inc
Application granted granted Critical
Publication of ATE509955T1 publication Critical patent/ATE509955T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02795695T 2001-11-26 2002-11-26 Humanisierte kollagen-antikörper und damit verbundene verfahren ATE509955T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/995,529 US7365167B2 (en) 2001-11-26 2001-11-26 Humanized collagen antibodies and related methods
US10/011,250 US7390885B2 (en) 2001-11-26 2001-12-06 Humanized collagen antibodies and related methods
PCT/US2002/038147 WO2003046204A2 (en) 2001-11-26 2002-11-26 Humanized collagen antibodies and related methods

Publications (1)

Publication Number Publication Date
ATE509955T1 true ATE509955T1 (de) 2011-06-15

Family

ID=26682164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02795695T ATE509955T1 (de) 2001-11-26 2002-11-26 Humanisierte kollagen-antikörper und damit verbundene verfahren

Country Status (11)

Country Link
US (4) US7390885B2 (de)
EP (1) EP1478764B1 (de)
JP (2) JP4519464B2 (de)
CN (1) CN1596313B (de)
AT (1) ATE509955T1 (de)
AU (1) AU2009200070A1 (de)
CA (1) CA2468016A1 (de)
IL (1) IL162117A0 (de)
MX (1) MXPA04004857A (de)
NZ (1) NZ533408A (de)
WO (1) WO2003046204A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
CA2555820C (en) 2004-02-19 2016-01-19 Genentech, Inc. Cdr-repaired antibodies
AU2006283174A1 (en) * 2005-08-24 2007-03-01 Cell-Matrix, Inc. Combination therapies for inhibiting integrin-extracellular matrix interactions
EP2054442A2 (de) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denaturierte collagen-peptide und anwendungen davon
ES2656359T3 (es) * 2006-06-30 2018-02-26 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
PT2099826E (pt) * 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2010055950A1 (ja) * 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療
ES2529101T3 (es) * 2009-03-30 2015-02-16 Nordic Bioscience A/S Ensayo de biomarcadores para fibrosis
US20120237504A1 (en) 2009-10-20 2012-09-20 Maine Medical Center Compositions and methods for treating inflammation and fibrosis
CN103068396B (zh) * 2010-03-02 2016-07-06 诺沃姆德治疗公司 抑制c5和备解素相互作用的抗-备解素抗体在制备抑制交替途径活化的药剂中的用途
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
EP2639243A4 (de) * 2010-11-10 2014-06-04 Nippon Kayaku Kk Antikörper gegen einsträngige collagen-polypeptide vom typ iv und pharmazeutikum oder wirkstoff zur diagnose, vorbeugung oder behandlung von tumoren damit
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
WO2014159915A1 (en) * 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Her3 specific monoclonal antibodies for diagnostic and therapeutic use
DK3515478T3 (da) * 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
AU2019242912B2 (en) 2018-03-28 2025-07-17 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in DNA isolated from exosomes
CN113507935A (zh) * 2018-10-16 2021-10-15 得克萨斯州大学系统董事会 用于诊断和治疗癌症及其他疾病的对致病性胞外基质的鉴定和靶向
WO2020102779A1 (en) * 2018-11-16 2020-05-22 Albert Einstein College Of Medicine MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
AU2020213565B2 (en) * 2019-01-28 2026-04-30 Tuojie Biotech (Shanghai) Co., Ltd. Anti-CD79B antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2021252974A2 (en) * 2020-06-11 2021-12-16 Proviva Therapeutics (Hong Kong) Limited Collagen-targeted fusion proteins and antibodies
WO2022147298A1 (en) * 2020-12-31 2022-07-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Vascular-endothelial cadherin activating antibodies and uses thereof
WO2024215985A1 (en) * 2023-04-13 2024-10-17 MaineHealth Compositions and methods for an antibody drug conjugate directed to a non-cell surface therapeutic target

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US91482A (en) * 1869-06-15 Improvement in harvesters
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
DE69114782T2 (de) * 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5871974A (en) 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
ES2145004T3 (es) 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
DE4127790A1 (de) 1991-08-22 1993-02-25 Wank Anna Verwendung von oligopeptiden mit 2 bis 5 peptidbindungen fuer kosmetische zwecke und einige neue oligopeptid-metallkomplexe
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH0675216A (ja) 1992-08-27 1994-03-18 Hitachi Ltd 液晶表示装置
US6132976A (en) * 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
CA2148132A1 (en) 1992-12-04 1994-06-23 Anthony Robin Poole Immunoassay for the measurement of collagen cleavage in cartilage
US5541295A (en) * 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
EP0711415B1 (de) 1993-07-28 1998-07-22 Boehringer Mannheim Gmbh Immunoassay zum nachweis von kollagen typ i oder kollagenfragmenten davon
US5510391A (en) 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
US5465826A (en) * 1994-02-24 1995-11-14 Valiant Machine & Tool, Inc. Conveyor system
US5560910A (en) 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5763272A (en) * 1994-12-23 1998-06-09 Boehringer Mannheim Gmbh Hybridoma for producing antibody for collagen I
US5756775A (en) * 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
WO1997039746A1 (en) 1996-04-22 1997-10-30 Advanced Polymer Systems, Inc. Method of and composition for treating disorders of the skin using vitamin k
WO1997044059A2 (en) 1996-05-23 1997-11-27 Shriner's Hospitals For Children Cartilage type ii collagen as an angiogenic factor
US6492508B1 (en) 1996-06-03 2002-12-10 United States Surgical Corp. A Division Of Tyco Healthcare Group Nucleic acids encoding extracellular matrix proteins
WO1999011208A1 (en) 1997-08-28 1999-03-11 Williams C Donald Method and composition for transdermal administration of pharmacologic agents
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
GB9702252D0 (en) 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay
US5817699A (en) * 1997-05-30 1998-10-06 Flores; John A. Process for the preparation of ketamine ointment
US5972623A (en) * 1997-07-31 1999-10-26 Metra Biosystems, Inc. Collagen-peptide assay method
AU8691398A (en) 1997-08-04 1999-02-22 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
US6030792A (en) 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
BR9915543A (pt) 1998-10-16 2001-08-14 Fraunhofer Ges Forschung Resistência a doenças por plantas mediada por patogenicidas moleculares
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU776137B2 (en) 1999-01-06 2004-08-26 University Of Southern California Method and composition for angiogenesis inhibition
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
ATE435031T1 (de) 1999-07-13 2009-07-15 Univ Southern California Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
ATE263375T1 (de) 1999-10-13 2004-04-15 Incyte Corp Multiple analyse von zytokinen
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE60130538T2 (de) 2000-02-03 2008-06-12 Millenium Pharmaceuticals, Inc., Cambridge Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
AU2001243515A1 (en) * 2000-03-08 2001-09-17 Rhode Island Hospital, A Lifespan Partner Combination drug therapy
US6696254B2 (en) 2001-11-21 2004-02-24 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20040241776A1 (en) 2003-05-22 2004-12-02 Agdia, Inc. Multiplex enzyme-linked immunosorbent assay for detecting multiple analytes
JP2005347062A (ja) 2004-06-02 2005-12-15 Hitachi Displays Ltd バックライト装置及び液晶表示装置
JP2006075216A (ja) 2004-09-07 2006-03-23 Toshiba Corp 医用画像処理システム、医用画像処理プログラムおよび医用画像処理方法
EP2054442A2 (de) 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denaturierte collagen-peptide und anwendungen davon

Also Published As

Publication number Publication date
IL162117A0 (en) 2005-11-20
AU2002360439A2 (en) 2003-06-10
EP1478764A2 (de) 2004-11-24
MXPA04004857A (es) 2005-04-11
AU2009200070A1 (en) 2009-02-05
JP2005510246A (ja) 2005-04-21
EP1478764A4 (de) 2007-05-23
US7390885B2 (en) 2008-06-24
EP1478764B1 (de) 2011-05-18
JP2009240324A (ja) 2009-10-22
WO2003046204A3 (en) 2004-09-23
US20080050388A1 (en) 2008-02-28
US20100303726A1 (en) 2010-12-02
US20080260733A1 (en) 2008-10-23
US7763248B2 (en) 2010-07-27
CN1596313B (zh) 2010-05-26
US20070077199A1 (en) 2007-04-05
WO2003046204A8 (en) 2004-07-08
WO2003046204A2 (en) 2003-06-05
CA2468016A1 (en) 2003-06-05
AU2002360439A1 (en) 2003-06-10
US7566770B2 (en) 2009-07-28
CN1596313A (zh) 2005-03-16
HK1076128A1 (zh) 2006-01-06
NZ533408A (en) 2006-06-30
JP4519464B2 (ja) 2010-08-04

Similar Documents

Publication Publication Date Title
IL162117A0 (en) Humanized collagen antibodies and methods utilizing the same
IN2009KN02655A (de)
IL220128A0 (en) Method for the humanization of antibodies and humanized antibodies thereby obtained
ATE454903T1 (de) Gegen menschliches ovarialkarzinom und gegen cd3 gerichteter bispezifischer antikörper
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
WO2003100008A3 (en) Neutralizing human anti-igfr antibody
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
GEP20074222B (en) Antibodies to cd40
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
CR20130151A (es) PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599)
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2003034903A3 (en) Psma antibodies and protein multimers
DK1308507T3 (da) Monoklonalt antistof mod HCV-kerneantigen
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
DE69029808D1 (de) Monoklonale antikörper
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
MX2007000103A (es) Bibliotecas de anticuerpos universales.
WO2022260995A3 (en) Materials and methods for differentiating creb regulated transcription coactivator 3

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties